- Home
- RARE vs AGYS Comparison
RARE vs AGYS Comparison
Compare RARE & AGYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- AGYS
- Stock Information
- Founded
- RARE 2010
- AGYS 1963
- Country
- RARE United States
- AGYS United States
- Employees
- RARE N/A
- AGYS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- AGYS EDP Services
- Sector
- RARE Health Care
- AGYS Technology
- Exchange
- RARE Nasdaq
- AGYS Nasdaq
- Market Cap
- RARE 3.5B
- AGYS 2.8B
- IPO Year
- RARE 2014
- AGYS N/A
- Fundamental
- Price
- RARE $36.68
- AGYS $117.00
- Analyst Decision
- RARE Strong Buy
- AGYS Strong Buy
- Analyst Count
- RARE 15
- AGYS 5
- Target Price
- RARE $90.53
- AGYS $125.20
- AVG Volume (30 Days)
- RARE 1.1M
- AGYS 268.9K
- Earning Date
- RARE 07-31-2025
- AGYS 07-21-2025
- Dividend Yield
- RARE N/A
- AGYS N/A
- EPS Growth
- RARE N/A
- AGYS N/A
- EPS
- RARE N/A
- AGYS 0.82
- Revenue
- RARE $590,689,000.00
- AGYS $275,624,000.00
- Revenue This Year
- RARE $18.94
- AGYS $14.61
- Revenue Next Year
- RARE $28.93
- AGYS $17.49
- P/E Ratio
- RARE N/A
- AGYS $140.10
- Revenue Growth
- RARE 33.46
- AGYS 16.07
- 52 Week Low
- RARE $29.59
- AGYS $63.71
- 52 Week High
- RARE $60.37
- AGYS $142.64
- Technical
- Relative Strength Index (RSI)
- RARE 51.86
- AGYS 61.89
- Support Level
- RARE $36.03
- AGYS $113.60
- Resistance Level
- RARE $37.74
- AGYS $116.26
- Average True Range (ATR)
- RARE 1.46
- AGYS 3.29
- MACD
- RARE -0.01
- AGYS -0.64
- Stochastic Oscillator
- RARE 26.56
- AGYS 47.86
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About AGYS Agilysys Inc.
Agilysys Inc provides hospitality software delivering cloud-native SaaS and on-premise solutions for hotels, resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It derives maximum revenue from the provision of software subscription and maintenance services, followed by the provision of professional services, and the sale of products (proprietary software licenses, third-party hardware, and operating systems). Agilysys operates across North America, Europe, the Middle East, Asia-Pacific, and India.